14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Price (Quote)

$38.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $38.22 $38.22 Friday, 27th May 2022 DRNA stock ended at $38.22. During the day the stock fluctuated 0% from a day low at $38.22 to a day high of $38.22.
90 days $38.22 $38.22
52 weeks $19.06 $40.14

Historical Dicerna Pharmaceuticals prices

Date Open High Low Close Volume
Nov 29, 2021 $37.98 $38.13 $37.96 $38.08 10 487 500
Nov 26, 2021 $37.97 $38.00 $37.94 $37.97 5 406 718
Nov 24, 2021 $37.98 $38.00 $37.96 $38.00 7 279 000
Nov 23, 2021 $37.91 $38.00 $37.91 $37.98 3 027 659
Nov 22, 2021 $37.92 $38.00 $37.90 $37.92 7 988 700
Nov 19, 2021 $37.97 $37.99 $37.92 $37.92 138 356
Nov 18, 2021 $37.95 $38.14 $37.90 $38.03 32 158 200
Nov 17, 2021 $21.33 $21.63 $21.18 $21.28 483 100
Nov 16, 2021 $21.19 $21.71 $20.87 $21.30 627 300
Nov 15, 2021 $22.26 $22.26 $21.12 $21.19 538 237
Nov 12, 2021 $22.35 $22.59 $21.74 $22.12 510 602
Nov 11, 2021 $21.73 $22.56 $21.73 $22.14 486 300
Nov 10, 2021 $22.08 $23.00 $21.61 $21.80 1 149 600
Nov 09, 2021 $22.50 $23.43 $22.02 $22.36 1 051 700
Nov 08, 2021 $21.96 $22.43 $21.72 $22.27 702 052
Nov 05, 2021 $22.38 $22.40 $21.17 $21.91 764 557
Nov 04, 2021 $21.75 $22.31 $21.05 $22.29 2 270 400
Nov 03, 2021 $20.95 $21.70 $20.86 $21.42 1 968 300
Nov 02, 2021 $21.19 $21.37 $20.54 $21.00 903 300
Nov 01, 2021 $20.90 $21.40 $20.69 $21.06 905 400
Oct 29, 2021 $21.38 $21.51 $20.77 $20.81 225 710
Oct 28, 2021 $21.66 $21.66 $20.92 $21.45 686 900
Oct 27, 2021 $21.44 $22.15 $21.41 $21.52 423 200
Oct 26, 2021 $21.59 $22.23 $21.41 $21.54 427 700
Oct 25, 2021 $21.78 $21.78 $20.79 $21.35 408 746
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT